Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sanofi-Aventis S.A. ADR (NQ: SNY ) 55.22 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sanofi-Aventis S.A. ADR < Previous 1 2 ... 23 24 25 26 27 28 29 30 Next > The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal June 22, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... Via Benzinga Sanofi, Translate Bio Initiate Early-Stage mRNA Influenza Vaccine Trial June 22, 2021 Sanofi Pasteur, vaccine unit of Sanofi SA (NASDAQ: SNY) and Translate Bio Inc (NASDAQ: TBIO) have initiated a Phase 1 trial evaluating an mRNA-based... Via Benzinga 5 Value Stocks To Watch In The Healthcare Sector June 21, 2021 A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... Via Benzinga How This Pharma Company Can Benefit From Its Competitors June 20, 2021 Delays in FDA approval for Incyte could spell good news for Sanofi. Via The Motley Fool Exposures Product Safety Europe Approves Sanofi's Expanded Use Of Aubagio In Pediatric Patients With Multiple Sclerosis June 18, 2021 The European Commission has approved Sanofi SA's (NASDAQ: SNY) Aubagio (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with... Via Benzinga BioNTech Starts Dosing In Mid-Stage Melanoma Vaccine Trial June 18, 2021 BioNTech SE (NASDAQ: BNTX) has dosed the first patient in its Phase 2 trial evaluating the BNT111 cancer vaccine. The study evaluates the therapeutic cancer... Via Benzinga Sanofi Scores FDA Approval For Flu-Shot Facility In US June 17, 2021 The FDA has approved Sanofi SA's (NASDAQ: SNY) newly completed plant in Swiftwater, Pennsylvania. The license will allow Sanofi to begin production of its... Via Benzinga Exposures Product Safety Elanco Is Looking To Challenge Zoetis, Will The $440 Million Kindred Buyout Help? June 16, 2021 Elanco Animal Health said Wednesday it would buy Kindred Biosciences for roughly $440 million, sending KIN stock soaring. Via Investor's Business Daily Sanofi's Sutimlimab Hits Endpoint Goal In Rare Anemia Study After FDA Rejection June 11, 2021 Sanofi SA’s (NASDAQ: SNY) sutimlimab nailed all three of its primary endpoints in its Phase 3 CADENZA study for patients with cold agglutinin disease. This... Via Benzinga Exposures Product Safety Elevation Oncology Files for $100M IPO June 07, 2021 Elevation Oncology has filed to raise $100 million in an IPO. See SEC prospectus here. Proceeds will be used to support the development of seribantumab that failed... Via Benzinga Topics Initial Public Offering Regulatory Compliance Exposures Legal Regulatory Securities Market Sanofi Inks Partnership for Late-Stage Trial of Amcenestrant as Add-On Breast Cancer Therapy June 04, 2021 Sanofi SA (NASDAQ: SNY) has secured partners for a Phase 3 trial to study amcenestrant versus the hormone therapy tamoxifen in breast cancer. The Breast... Via Benzinga The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact June 04, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3) BioCryst Pharmaceuticals,... Via Benzinga Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics June 03, 2021 The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or... Via Benzinga P/E Ratio Insights for Sanofi June 01, 2021 In the current market session, Sanofi Inc. (NASDAQ:SNY) is trading at $52.60, after a 1.55% decrease. However, over the past month, the stock spiked by 4.32%, and in... Via Benzinga Sanofi Stops Venglustat Development In Rare Genetic Kidney Disorder June 01, 2021 Sanofi SA (NASDAQ: SNY) has halted the clinical program of venglustat in autosomal dominant polycystic kidney disease (ADPKD). Although the safety profile of... Via Benzinga Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine May 27, 2021 Sanofi SA and GlaxoSmithKline plc have launched a Phase 3 trial for its recombinant COVID-19 vaccine candidate, which they hope to get approved by the end of 2021. Via Talk Markets Exposures COVID-19 Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine May 27, 2021 Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) have launched a Phase 3 trial for its recombinant COVID-19 vaccine candidate, which they hope... Via Benzinga Exposures COVID-19 The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs May 27, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... Via Benzinga Exposures COVID-19 Sanofi, Walvax COVID-19 Vaccine Phase 3 Trials to Commence in Mexico: Reuters May 25, 2021 Mexico Foreign Minister Marcel Ebrard said that the country would begin phase 3 trials for COVID-19 vaccines by Sanofi SA (NASDAQ: SNY) and China's Walvax... Via Benzinga Exposures COVID-19 Regeneron-Sanofi's Libtayo Scores CHMP's Positive Opinion For Two Advanced Cancer Settings May 24, 2021 The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Regeneron Pharmaceuticals Inc (... Via Benzinga Sanofi's Amcenestrant Combo Therapy Shows ORR of 34% In Breast Cancer Patients May 20, 2021 Sanofi SA (NASDAQ: SNY) revealed a new early peek at data from breast cancer candidate amcenestrant, an oral selective estrogen receptor degrader. Data will be... Via Benzinga Eli Lilly's Tirzepatide Non-Inferior To Titrated Insulin Glargine In Type 2 Diabetes Patients May 20, 2021 Eli Lilly and Co (NYSE: LLY) has reported topline data from Phase 3 SURPASS-4 clinical trial evaluating tirzepatide in adults with type 2 diabetes and increased... Via Benzinga Better Buy for 2021: GlaxoSmithKline or Sanofi? May 20, 2021 These are two cheap stocks in an overvalued market. Via The Motley Fool GlaxoSmithKline-Medicago's COVID-19 Vaccine Candidate Elicit Strong Immune Response May 18, 2021 Interim Phase 2 trial results of GlaxoSmithKline plc (NYSE: GSK) and its collaborating partner Medicago Inc’s COVID-19 vaccine candidate showed... Via Benzinga Exposures COVID-19 Another Tough Day For Markets May 17, 2021 The stock market resumed its negativism today mainly linked to fear of inflation and higher interest rates, on the argument that the most dangerous thing to believe is “it's different this time.” Via Talk Markets Sanofi-Regeneron Tout New Data For Dupixent From Pediatric Asthma Trial May 17, 2021 Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have unveiled detailed results from a Phase 3 trial evaluating Dupixent... Via Benzinga A Look Into Healthcare Sector Value Stocks May 17, 2021 What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... Via Benzinga Sanofi-GSK's COVID-19 Vaccine Candidate Reports Success In Mid-Stage Study May 17, 2021 Sanofi SA (NASDAQ: SNY) and its collaborating partner GlaxoSmithKline plc (NYSE: GSK) have reported "strong immune responses" in early tests of... Via Benzinga Exposures COVID-19 The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off May 15, 2021 Biotech stocks had a volatile ride in the week ended May 14, with stocks moving lower for much of the week before coming back up strongly in the final session. Some of the weakness may be traced back... Via Talk Markets Exposures Product Safety The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off May 15, 2021 Biotech stocks had a volatile ride in the week ended May 14, with stocks moving broadly lower for much of the week before coming back up strongly in the final session. Some of the... Via Benzinga Exposures Product Safety < Previous 1 2 ... 23 24 25 26 27 28 29 30 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.